LentiPro26: Novel stable cell lines for constitutive lentiviral vector production

H. A. Tomás, A. F. Rodrigues, M. J.T. Carrondo, A. S. Coroadinha

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)
93 Downloads (Pure)


Lentiviral vectors (LVs) are excellent tools to promote gene transfer and stable gene expression. Their potential has been already demonstrated in gene therapy clinical trials for the treatment of diverse disorders. For large scale LV production, a stable producer system is desirable since it allows scalable and cost-effective viral productions, with increased reproducibility and safety. However, the development of stable systems has been challenging and time-consuming, being the selection of cells presenting high expression levels of Gag-Pro-Pol polyprotein and the cytotoxicity associated with some viral components, the main limitations. Hereby is described the establishment of a new LV producer cell line using a mutated less active viral protease to overcome potential cytotoxic limitations. The stable transfection of bicistronic expression cassettes with re-initiation of the translation mechanism enabled the generation of LentiPro26 packaging populations supporting high titers. Additionally, by skipping intermediate clone screening steps and performing only one final clone screening, it was possible to save time and generate LentiPro26-A59 cell line, that constitutively produces titers above 106 TU.mL-1.day-1, in less than six months. This work constitutes a step forward towards the development of improved LV producer cell lines, aiming to efficiently supply the clinical expanding gene therapy applications.

Original languageEnglish
Article number5271
JournalScientific Reports
Issue number1
Publication statusPublished - 1 Dec 2018


Dive into the research topics of 'LentiPro26: Novel stable cell lines for constitutive lentiviral vector production'. Together they form a unique fingerprint.

Cite this